Special Issue

Biological Basis of Anti-tumor Therapies

Message from the Guest Editor

Cancer treatment is undoubtedly one of the greatest challenges of this century. Current knowledge on the nature of cancer has taught the scientific community that cancer must be treated according to the needs of each specific patient, introducing the concept of "personalized medicine", a therapeutic approach capable of adapting not only to different types of cancer, but especially to different patients with the same type of cancer. These concepts have given rise to a series of new therapeutic approaches, aimed at the personalization of therapies, focusing the efforts of researchers on new topics such as personalized vaccines, cell therapy, gene editing, the microbiome and in particular the individual enteroma. These new approaches can be helped by therapeutic interventions aimed at controlling characteristics "shared" by the majority of tumors but that may be differentially expressed in each single patients, such as the mechanisms of acidification of the tumor microenvironment, the aberrant formation of blood vessels, the major factors that control invasive and metastatic processes, the differential presence of stem cells in the primary and metastatic tumors.

Guest Editor

Prof. Mario Del Rosso

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/71198

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

